Tumor-targeting CTL expressing a single-chain Fv specific for VEGFR2

Biochemical and Biophysical Research Communications

Volumn 394, Issue 1, 2010, Pages 54-58

  Kanagawa, Naoko ^a   Yanagawa, Tatsuya ^a   Mukai, Yohei ^a   Yoshioka, Yasuo ^a   Okada, Naoki ^a   Nakagawa, Shinsaku ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Adoptive immunotherapy; Cytotoxic T lymphocyte; scFv; Targeting; VEGFR2

Indexed keywords

RETROVIRUS VECTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CYTOTOXIC T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; CELL LINE, TUMOR; GENETIC ENGINEERING; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED C57BL; NEOPLASMS; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTES, CYTOTOXIC; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

MUS;

EID: 77949873398     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.02.085     Document Type: Article

References (26)

1. Kanagawa N., Niwa M., Hatanaka Y., Tani Y., Nakagawa S., Fujita T., Yamamoto A., and Okada N. CC-chemokine ligand 17 gene therapy induces tumor regression through augmentation of tumor-infiltrating immune cells in a murine model of preexisting CT26 colon carcinoma. Int. J. Cancer 121 (2007) 2013-2022
2. Gao J.Q., Tsuda T., Han M., Xu D.H., Kanagawa N., Hatanaka Y., Tani Y., Mizuguchi H., Tsutsumi Y., Mayumi T., Okada N., and Nakagawa S. NK cells are migrated and indispensable in the anti-tumor activity induced by CCL27 gene therapy. Cancer Immunol. Immunother. 58 (2009) 291-299
3. Gao J.Q., Kanagawa N., Motomura Y., Yanagawa T., Sugita T., Hatanaka Y., Tani Y., Mizuguchi H., Tsutsumi Y., Mayumi T., Okada N., and Nakagawa S. Cotransduction of CCL27 gene can improve the efficacy and safety of IL-12 gene therapy for cancer. Gene Ther. 14 (2007) 491-502
4. Boon T., Coulie P.G., Van den Eynde B.J., and van der Bruggen P. Human T cell responses against melanoma. Annu. Rev. Immunol. 24 (2006) 175-208
5. Zitvogel L., Tesniere A., and Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6 (2006) 715-727
6. Gattinoni L., Powell Jr. D.J., Rosenberg S.A., and Restifo N.P. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6 (2006) 383-393
7. Fang L., Lonsdorf A.S., and Hwang S.T. Immunotherapy for advanced melanoma. J. Invest. Dermatol. 128 (2008) 2596-2605
8. Stauss H.J., Cesco-Gaspere M., Thomas S., Hart D.P., Xue S.A., Holler A., Wright G., Perro M., Little A.M., Pospori C., King J., and Morris E.C. Monoclonal T-cell receptors: new reagents for cancer therapy. Mol. Ther. 15 (2007) 1744-1750
9. de Witte M.A., Jorritsma A., Kaiser A., van den Boom M.D., Dokter M., Bendle G.M., Haanen J.B., and Schumacher T.N. Requirements for effective antitumor responses of TCR transduced T cells. J. Immunol. 181 (2008) 5128-5136
10. Eerola A.K., Soini Y., and Pääkkö P. A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin. Cancer Res. 6 (2000) 1875-1881
11. Naito Y., Saito K., Shiiba K., Ohuchi A., Saigenji K., Nagura H., and Ohtani H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58 (1998) 3491-3494
12. Brown L.F., Berse B., Jackman R.W., Tognazzi K., Manseau E.J., Dvorak H.F., and Senger D.R. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol. 143 (1993) 1255-1262
13. Plate K.H., Breier G., Millauer B., Ullrich A., and Risau W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res. 53 (1993) 5822-5827
14. Ramakrishnan S., Olson T.A., Bautch V.L., and Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res. 56 (1996) 1324-1330
15. Mohr L., Yeung A., Aloman C., Wittrup D., and Wands J.R. Antibody-directed therapy for human hepatocellular carcinoma. Gastroenterology 127 (2004) S225-S231
16. Shen S., Forero A., LoBuglio A.F., Breitz H., Khazaeli M.B., Fisher D.R., Wang W., and Meredith R.F.. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J. Nucl. Med. 46 (2005) 642-651
17. Morita S., Kojima T., and Kitamura T.. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 7 (2000) 1063-1066
18. Kataoka H., Takakura N., Nishikawa S., Tsuchida K., Kodama H., Kunisada T., Risau W., Kita T., and Nishikawa S.I. Expressions of PDGF receptor alpha, c-Kit and Flk1 genes clustering in mouse chromosome 5 define distinct subsets of nascent mesodermal cells. Dev. Growth Differ. 39 (1997) 729-740
19. Kitamura T., Koshino Y., Shibata F., Oki T., Nakajima H., Nosaka T., and Kumagai H. Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp. Hematol. 31 (2003) 1007-1014
20. Kanagawa N., Koretomo R., Murakami S., Sakurai F., Mizuguchi H., Nakagawa S., Fujita T., Yamamoto A., and Okada N. Factors involved in the maturation of murine dendritic cells transduced with adenoviral vector variants. Virology 374 (2008) 411-420
21. Okada N., Masunaga Y., Okada Y., Iiyama S., Mori N., Tsuda T., Matsubara A., Mizuguchi H., Hayakawa T., Fujita T., and Yamamoto A. Gene transduction efficiency and maturation status in mouse bone marrow-derived dendritic cells infected with conventional or RGD fiber-mutant adenovirus vectors. Cancer Gene Ther. 10 (2003) 421-431
22. Menon A.G., Janssen-van Rhijn C.M., Morreau H., Putter H., Tollenaar R.A., van de Velde C.J., Fleuren G.J., and Kuppen P.J. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab. Invest. 84 (2004) 493-501
23. Bakker A.B., Marland G., de Boer A.J., Huijbens R.J., Danen E.H., Adema G.J., and Figdor C.G. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res. 55 (1995) 5330-5334
24. Kawakami Y., Eliyahu S., Jennings C., Sakaguchi K., Kang X., Southwood S., Robbins P.F., Sette A., Appella E., and Rosenberg S.A. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154 (1995) 3961-3968
25. Takita M., Matsumura T., and Kami M. Cytokine storm and an anti-CD28 monoclonal antibody. N. Engl. J. Med. 355 (2006) 2593
26. Stebbings R., Findlay L., Edwards C., Eastwood D., Bird C., North D., Mistry Y., Dilger P., Liefooghe E., Cludts I., Fox B., Tarrant G., Robinson J., Meager T., Dolman C., Thorpe S.J., Bristow A., Wadhwa M., Thorpe R., and Poole S. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J. Immunol. 179 (2007) 3325-3331